Patients & Families
Mirum is focused on developing a safe and effective treatment for children with rare cholestatic liver diseases. What we want, more than anything, is to enable patients and their families to live a healthy and happy life, liberated from around-the-clock disruptions of disease.
We are currently advancing maralixibat for the treatment of Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC), for which there are no approved therapeutics.
Genetic Testing
Mirum Pharmaceuticals is partnering with Retrophin, Inc., to provide, to qualified patients at no charge, the EGL Genetic Cholestasis Panel. This panel may assist in diagnosing a child who has one of these cholestatic liver diseases. For more information about how to access this program, please contact clinicaltrials@mirumpharma.com.